Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420. Blood. 2015. PMID: 26359434 Free article. Clinical Trial. No abstract available.
Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA, Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Tassidou A, Terpos E. Dimopoulos MA, et al. Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015. Clin Lymphoma Myeloma. 2009. PMID: 19362975 Review.
Emerging drugs for Waldenström's macroglobulinemia.
Kastritis E, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Expert Opin Emerg Drugs. 2011 Mar;16(1):45-57. doi: 10.1517/14728214.2011.523418. Expert Opin Emerg Drugs. 2011. PMID: 21352069 Review.
Bortezomib for AL amyloidosis: moving forward.
Dimopoulos MA, Kastritis E. Dimopoulos MA, et al. Blood. 2011 Jul 28;118(4):827-8. doi: 10.1182/blood-2011-05-355115. Blood. 2011. PMID: 21799093 Free article. No abstract available.
When a little aspirin may be enough.
Kastritis E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood. 2012 Jan 26;119(4):905-6. doi: 10.1182/blood-2011-08-375089. Blood. 2012. PMID: 22282490 Free article.
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.
Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood. 2012 Jun 7;119(23):5384-90. doi: 10.1182/blood-2011-12-396903. Epub 2012 Apr 18. Blood. 2012. PMID: 22517904 Free article. Clinical Trial.
VWF, WM, and angiogenesis: is there a link?
Kastritis E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood. 2012 Oct 18;120(16):3163-4. doi: 10.1182/blood-2012-08-451468. Blood. 2012. PMID: 23086619 Free article. No abstract available.
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA, García-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Kastritis E, Sonneveld P. Dimopoulos MA, et al. Blood. 2013 Nov 7;122(19):3276-82. doi: 10.1182/blood-2013-05-503862. Epub 2013 Sep 4. Blood. 2013. PMID: 24004667 Free article. Clinical Trial.
Less strength and more fractures for MGUS bones.
Terpos E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood. 2014 Jan 30;123(5):603-4. doi: 10.1182/blood-2013-11-539973. Blood. 2014. PMID: 24482495 Free article.
1,275 results